🔴 Website 👉 https://u-s-news.com/
Telegram 👉 https://t.me/usnewscom_channel
Peter Marks, the former head of the FDA’s Center for Biologics Evaluation and Research (CBER) and a prominent critic of Health and Human Services (HHS) Secretary Robert F. Kennedy Jr., landed a new job at pharma giant Eli Lilly.
Marks will join the company as senior vice president of molecule discovery and head of infectious disease.
“Peter’s expertise strengthens our abilities across multiple areas, both in our existing portfolio and in our work in emerging areas,” a company spokesperson said.
NEW — Pharma Giant Eli Lilly Hires Ex-FDA Vaccine Regulator, Peter Marks, to Head Infectious Disease Unit
“Peter’s expertise strengthens our abilities across multiple areas, both in our existing portfolio and in our work in emerging areas,” the company said. pic.twitter.com/eeJrpcLCrA
— Chief Nerd (@TheChiefNerd) October 7, 2025
Marks, who held his position in the federal agency for nearly a decade, reportedly clashed with RFK Jr. on vaccine policy.
Fierce Biotech explained:
Early in the new Trump administration, Marks’ disagreements with RFK Jr. over vaccines led to his departure in what was possibly the most high-profile FDA exit of the year. In his resignation letter (PDF), Marks wrote that he hoped the “unprecedented assault on scientific truth” would end “so that the citizens of our country can fully benefit from the breadth of advances in medical science.”
During his time at the FDA, Marks advocated for the agency’s accelerated approval pathway for rare diseases and gene therapies, and he played a critical role in the speedy advancement of COVID-19 vaccines in response to the pandemic.
Marks’ jump to a Big Pharma company that he used to regulate is the latest example of the revolving door between government and industry, which has frequently set ethical alarm bells ringing. For example, former FDA Commissioner Scott Gottlieb, M.D., snagged a spot on Pfizer’s board of directors just three months after leaving his government post in 2019.
A couple months before Marks left the FDA, his counterpart at the agency’s Center for Drug Evaluation and Research, Patrizia Cavazzoni, M.D., resigned and eventually ended up at Pfizer, where she serves as chief medical officer and executive vice president.
“Revolving door alert,” MAHA Action stated.
“Peter Marks, the former FDA vaccine chief, just joined Eli Lilly to lead infectious disease research. From regulator to pharma insider, a story we seem to hear over and over. It’s ironic how the loudest critics of RFK Jr. and the MAHA movement are the same ones cashing in while Americans’ health keeps deteriorating,” it added.
🚨Revolving door alert🚨
Peter Marks, the former FDA vaccine chief, just joined Eli Lilly to lead infectious disease research.
From regulator to pharma insider, a story we seem to hear over and over.
It’s ironic how the loudest critics of RFK Jr. and the MAHA movement are the… pic.twitter.com/GddtTzLAS4
— MAHA Action (@MAHA_Action) October 7, 2025
CBS News reported earlier this year:
The resignation by Marks caps a decades-long and sometimes controversial tenure at the agency as its top official on biologics products, which include vaccines as well as other treatments like cell and gene based therapies, and blood donations.
Marks has faced criticism for his role in several decisions overruling his staff and outside advisers, like in the approval of the Alzheimer’s drug Aduhelm or greenlighting COVID-19 vaccine boosters.
During the COVID-19 pandemic, federal officials credited Marks for creating the Operation Warp Speed effort that accelerated the development of COVID-19 vaccines under President Trump’s first term.
“He is Operation Warp Speed. Lots of people take credit inappropriately and overstate their contributions,” one current senior federal health official said.
“It was Peter’s vision that made that work possible,” the official added.